The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Among them is first-in-class anti-CD40 antibody iscalimab (CFZ533), which showed in a study reported this summer that it may be able to prolong the life of transplanted kidneys, which can ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 7.68%, which has investors questioning if this is right time to ...